Finding right balance between high-throughput sequencing and related bioinformatics analysis

Balancing high-throughput sequencing and related bioinformatics analysis between a research group’s internal efforts and specialized service providers can both speed results to difficult biological questions and provide cost-effective access to the latest technology, says Eureka Genomics (EG). The company’s unique capabilities and services and how they can help in “Finding the Right Balance” will be the topic of discussion at a “Java and Jive” session on Wednesday March 17, 8:15 am at the Now-Generation Sequencing conference being held at the Hilton San Diego Resort in San Diego, CA.

“We take pride in developing a consultive relationship with each and every client”

“We take pride in developing a consultive relationship with each and every client,” said Heather Koshinsky, Ph.D., Eureka Genomics’ Chief Scientific Officer. “As biologists ourselves, we understand that proper experimental design and library preparation all add to the quality of the sequencing. This, followed by application of the most appropriate bioinformatics tools, results in EG’s ability to solve our customers’ biggest genomics questions.” EG’s robust, proprietary and highly efficient algorithms use an “exact” model, avoiding a heuristic approximation approach, and together have yielded solutions to previously intractable biological problems.

“As a manufacturer of automated sample preparation instrumentation, IntegenX concentrates on reliability, reproducibility and full integration of applications. As we develop a NGS library preparation application, Eureka Genomics has provided IntegenX not only cost effective and timely results, but their bioinformatics capability let us know immediately the high quality of our automated NGS library preparations,” said Stevan Jovanovich, Ph.D., President and Chief Executive Officer of IntegenX.

Range of Services and Latest Technologies

Eureka Genomics offers a range of services, from library generation from a variety of samples types, to sequence data analysis and gene annotation. Cutting-edge technological capabilities developed in support of the company’s own discovery efforts are applied to its service customer’s everyday problems.

“This sets us apart from the competition,” Dr. Koshinsky continued. “We excel in both the 'routine' and the 'non-routine,' and thus can offer the complete solutions to our customers’ problems when needed, or can address the simplest request.” EG currently performs data generation with the Illumina GAIIx but plans to add access to other sequencing platforms based on its customers’ interests.

Expanding Services Globally

Building off the successful close of $3.7mil in financing last week, Eureka Genomics announced that some of this funding will be used to grow their service organization and to continue their goal for “Best in Breed" among the growing field of high-throughput sequencing and bioinformatics service providers. EG plans to grow its global sales and marketing and expand its service offerings into Europe and South East Asia.

Source Eureka Genomics

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
ERS Genomics and medicines discovery catapult sign CRISPR/Cas9 license agreement